


-233-


95. The combination of Claim 90 wherein the cyclooxygenase-2 inhibitor is



5

rofecoxib, 4-(4-(methanesulfonyl)phenyl)-3-phenyl-2(5H)-furanone.

96. The combination of Claim 90 wherein the cyclooxygenase-2 inhibitor is



10

4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide.

97. The method of Claim 1 wherein the antineoplastic agent is anastrozole.

98. The method of Claim 1 wherein the antineoplastic agent is calcium carbonate.

99. The method of claim 1 wherein the antineoplastic agent is exemestane.

100. The method of claim 44 wherein the antineoplastic agent is exemestane.

101. The method of claim 90 wherein the antineoplastic agent is exemestane.

102. The method of Claim 44 wherein the combination is administered in a sequential manner.


-234-

103. The method of Claim 44 wherein the combination
is administered in a substantially simultaneous manner.

2025 RELEASE UNDER E.O. 14176

-233-


95. The combination of Claim 90 wherein the cyclooxygenase-2 inhibitor is



5

rofecoxib, 4-(4-(methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone.

96. The combination of Claim 90 wherein the cyclooxygenase-2 inhibitor is



10

4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide.

97

91. The method of Claim 1 wherein the antineoplastic agent is anastrozole.

98

92. The method of Claim 1 wherein the antineoplastic agent is calcium carbonate.

15

99

93. The method of claim 1 wherein the antineoplastic agent is exemestane.

100

94. The method of claim 44 wherein the antineoplastic agent is exemestane.

20

101

95. The method of claim 90 wherein the antineoplastic agent is exemestane.

102

98. The method of Claim 44 wherein the combination is administered in a sequential manner.